/
Nephrology
Renal Insufficiency
14
Pipeline Programs↗
10
Active Trials↗
24
Companies Involved↗
Renal insufficiency is an emerging landscape with 14 programs across 24 companies. The most active players are Rhythm Pharmaceuticals, Beijing Continent Pharmaceutical Co, Ltd., Sun Pharmaceutical Industries Limited.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical6
Phase 13
Phase 25
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
86%
Small molecule
12 of 14 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 14 classified programs, each share of the total. Modality classified for 100% of 14 pipeline programs.
Analysis
Trial Status
87
clinical trials
Completed55 · 63%
Terminated15 · 17%
Recruiting8 · 9%
Unknown status5 · 6%
Active, not recruiting2 · 2%
Withdrawn2 · 2%
Clinical Trials
Trial Activity
87 trials
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)